Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?

References

• LoftusEVJrClinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influencesGastroenterology20041261504151715168363
   PubMed Web of Science ®Google Scholar
• MolodeckyNASoonISRabiDMIncreasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic reviewGastroenterology20111424654 e4222001864
   PubMed Web of Science ®Google Scholar
• ParkKTBassDInflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a reviewInflamm Bowel Dis2011171603160921053357
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseNew Eng J Med2004350987688514985485
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut20075691232123917299059
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSPRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s diseaseNew Eng J Med2007357322823817634458
   PubMed Web of Science ®Google Scholar
• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisNew Eng J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut201160678078721209123
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCPURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology2014146196109 e123770005
   PubMed Web of Science ®Google Scholar
• FordACSandbornWJKhanKJHanauerSBTalleyNJMoayyediPEfficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysisAm J Gastroenterol20111064644659 quiz 66021407183
   PubMed Web of Science ®Google Scholar
• AllenPBPeyrin-BirouletLMoving towards disease modification in inflammatory bowel disease therapyCurr Opin Gastroenterol201329439740423695427
   PubMed Web of Science ®Google Scholar
• McLeanLPShea-DonohueTCrossRKVedolizumab for the treatment of ulcerative colitis and Crohn’s diseaseImmunotherapy20124988389823046232
   PubMed Web of Science ®Google Scholar
• LichtensteinGRPanaccioneRMallarkeyGEfficacy and safety of adalimumab in Crohn’s diseaseTherap Adv Gastroenterol2008114350
   PubMedGoogle Scholar
• McDermottEMurphySKeeganDO’DonoghueDMulcahyHDohertyGEfficacy of Adalimumab as a long term maintenance therapy in ulcerative colitisJ Crohns Colitis20137215015322520592
   PubMed Web of Science ®Google Scholar
• Ben-HorinSChowersYReview article: loss of response to anti-TNF treatments in Crohn’s diseaseAliment Pharmacol Ther201133998799521366636
   PubMed Web of Science ®Google Scholar
• AfifWLoftusEVFaubionWAClinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel diseaseAm J Gastroenterol201010551133113920145610
   PubMed Web of Science ®Google Scholar
• LeungYPanaccioneRAnti-adhesion molecule strategies for Crohn diseaseBio Drugs2008224259264
   Google Scholar
• GisbertJPPanésJLoss of response and requirement of infliximab dose intensification in Crohn’s disease: a reviewAm J Gastroenterol2009104376076719174781
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialAnn Intern Med20071461282983817470824
   PubMed Web of Science ®Google Scholar
• RutgeertsPvan AsscheGVermeireSOptimizing anti-TNF treatment in inflammatory bowel diseaseGastroenterology200412661593161015168370
   PubMed Web of Science ®Google Scholar
• GhoshSPanaccioneRAnti-adhesion molecule therapy for inflammatory bowel diseaseTherap Adv Gastroenterol201034239258
   PubMedGoogle Scholar
• CominelliFInhibition of leukocyte trafficking in inflammatory bowel diseaseNew Eng J Med2013369877577623964940
   PubMed Web of Science ®Google Scholar
• FussIJHellerFBoirivantMNonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitisJ Clin Invest20041131490149715146247
   PubMed Web of Science ®Google Scholar
• BevilacquaMPEndothelial-leukocyte adhesion moleculesAnnu Rev Immunol1993117678048476577
   PubMed Web of Science ®Google Scholar
• Van AsscheGRutgeertsPPhysiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel diseaseAm J Physiol Gastrointest Liver Physiol20052882G169G17415647604
   PubMed Web of Science ®Google Scholar
• HolmesDIntegrin inhibitors go with the gutNat Rev Drug Discov201312641141223722331
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGFedorakRNInternational Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE TrialGastroenterology200713251672168317484865
   PubMed Web of Science ®Google Scholar
• SandbornWJThe future of inflammatory bowel disease therapy: where do we go from here? Dig Dis201230Suppl 314014423295705
   PubMed Web of Science ®Google Scholar
• DaneseSNew therapies for inflammatory bowel disease: from the bench to the bedsideGut201261691893222115827
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety CommunicationNew risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab) [webpage on the Internet]Center for Drug Evaluation and Research2012 [cited January 20, 2012] Available from http://www.fda.gov/Drugs/DrugSafety/ucm288186.htmAccessed October 30, 2013
   Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyNew Eng J Med2012366201870188022591293
   PubMed Web of Science ®Google Scholar
• VermerschPKapposLGoldRClinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology201176201697170421576685
   PubMed Web of Science ®Google Scholar
• MilchCWyantTXuJVedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeJ Neuroimmunol20132641–212312624067534
   PubMed Web of Science ®Google Scholar
• AllenPBAnti-adhesion molecules: is gut specificity the key for a good safety profile? Curr Drug Deliv2012933333722762276
   PubMed Web of Science ®Google Scholar
• FedykERWyantTYangL-LExclusive antagonism of the α(4) β(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primatesInflamm Bowel Dis2012182107211922419649
   PubMed Web of Science ®Google Scholar
• FeaganBMacdonaldJGreenbergGAn ascending dose of a humanized alpha 4 beta 7 antibody in ulcerative colitis (UC)Gastroenterology20001184A874.21
   Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGTreatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinNew Eng J Med2005352242499250715958805
   PubMed Web of Science ®Google Scholar
• ParikhALeachTWyantTVedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyInflammat Bowel Dis20121814701479
   PubMed Web of Science ®Google Scholar
• ParikhALeachTXuJFeaganBLong-term clinical experience with vedolizumab (VDZ) in patients with mild to moderate ulcerative colitis (UC)J Crohns Colitis20126S103
   Google Scholar
• FeaganBGGreenbergGRWildGTreatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrinClin Gastroenterol Hepatol20086121370137718829392
   PubMed Web of Science ®Google Scholar
• SolerDChapmanTYangL-LWyantTEganRFedykERThe binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseasesJ Pharmacol Exp Ther200933086487519509315
   PubMed Web of Science ®Google Scholar
• MarshallJKLDP-02 (Millenium)Curr Opin Investig Drugs20012502504
   PubMedGoogle Scholar
• PetrovicAAlpdoganOWillisLMLPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host diseaseBlood20041031542154714563643
   PubMed Web of Science ®Google Scholar
• GledhillTBodgerKNew and emerging treatments for ulcerative colitis: a focus on vedolizumabBiologics2013712313023723689
   PubMedGoogle Scholar
• SouzaHSEliaCCSpencerJMacDonaldTTExpression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel diseaseGut19994585686310562584
   PubMed Web of Science ®Google Scholar
• MeenanJSpaansJGroolTAAltered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammationGut1997402412469071939
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPGEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s diseaseNew Eng J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• FeaganBGRutgeertsPSandsBEGEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitisNew Eng J Med2013369869971023964932
   PubMed Web of Science ®Google Scholar
• AllenPBKammMAPeyrin-BirouletLDevelopment and validation of a patient-reported disability measurement tool for patients with inflammatory bowel diseaseAliment Pharmacol Therap201337443844423278192
   PubMed Web of Science ®Google Scholar
• DaneseSFiocchiCUlcerative colitisNew Eng J Med2011365181713172522047562
   PubMed Web of Science ®Google Scholar
• NICEManagement of ulcerative colitisNICE Guidelines62013 Available from http://publications.nice.org.uk/ulcerative-colitis-cg166Accessed September 14, 2013
   Google Scholar
• BittonABuieDEnnsRCanadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statementsAm J Gastroenterol20121072179194 author reply 19522108451
   PubMed Web of Science ®Google Scholar
• HesterbergPEWinsor-HinesDBriskinMJRapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology19961115137313808898653
   PubMed Web of Science ®Google Scholar
• BaronJHConnellAMLennard-JonesJEVariation between observers in describing mucosal appearances in proctocolitisBMJ196415375899214075156
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized studyNew Eng J Med198731726162516293317057
   PubMed Web of Science ®Google Scholar
• FeaganBGRutgeertsPJSandsBE943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trialGastroenterology20121425S160S161
   Google Scholar
• RutgeertsPJVedolizumab maintenance therapy for ulcerative colitis (uc): results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trialGut201261supp 3A65
   Google Scholar
• LapidusABernellOHellersGLöfbergRClinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patientsGastroenterology19981146115111609609751
   PubMed Web of Science ®Google Scholar
• MowatCColeAWindsorAIBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adultsGut201160557160721464096
   PubMed Web of Science ®Google Scholar
• BaumgartDCVeto on vedolizumab (MLN0002) for Crohn’s diseaseInflammat Bowel Dis2010163537538
   Web of Science ®Google Scholar
• SandbornWSandsBEColombelJFVedolizumab induction therapy for Crohns Disease: results of GEMINI II, a randomized, placebo controlled, double-blind, multi-center phase 3 trial. P395Annual Scientific Meeting Abstracts2012Las Vegas, NVAmerican College of Gastroenterology
   Google Scholar
• MosliMHFeaganBGVedolizumab for Crohn’s diseaseExpert Opin Biol Ther20131345546323394379
   PubMed Web of Science ®Google Scholar
• Millennium Pharmaceuticals IncAn open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn’s disease Available from: http://clinicaltrials.gov/show/NCT00790933. NLM identifier: NCT00790933Accessed October 15, 2013
   Google Scholar
• Peyrin-BirouletLFerranteMMagroFScientific Committee of the European Crohn’s and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel diseaseJ Crohns Colitis20115547748321939925
   PubMed Web of Science ®Google Scholar
• FiorinoGCorrealeCFriesWRepiciAMalesciADaneseSLeukocyte traffic control: a novel therapeutic strategy for inflammatory bowel diseaseExpert Rev Clin Immunol20106456757220594130
   PubMed Web of Science ®Google Scholar